Yu Shan, Wang Yan, Cheng Xi, Lv Minzhi, Cui Yuehong, Li Wei, Yu Yiyi, Li Qian, Liu Tianshu
Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, People's Republic of China.
Cancer Manag Res. 2020 Oct 13;12:10091-10101. doi: 10.2147/CMAR.S270387. eCollection 2020.
To compare the prognosis of adjuvant SOX (S-1 and oxaliplatin) vs XELOX (capecitabine and oxaliplatin) chemotherapy in Chinese patients with gastric cancer (GC) after D2 gastrectomy.
This was a real-world study of patients with GC (stages II-III) who underwent D2 gastrectomy and received adjuvant SOX or XELOX between 01/2010 and 06/2017 in Zhongshan Hospital affiliated to Fudan University. The patients were matched by propensity score matching. The primary and secondary endpoints were disease-free survival (DFS) and overall survival (OS), respectively. Adverse events (AEs) were compared.
A total of 552 patients were included. The median follow-up time was 24.9 months. There were no differences in DFS (median, 44.4 vs 41.2 months; HR=1.17, 95% CI: 0.92-1.48) and OS (median, 61.5 vs 65.3 months; HR=1.01, 95% CI: 0.73-1.39) between the XELOX and SOX groups. Both DFS and OS had no significant differences between SOX and XELOX for all subgroups based on sex (P=0.949, P=0.990), age (P=0.303, P=0.392), Lauren type (P=0.362, P=0.573), type of gastrectomy (P=0.607 P=0.989), and pathological TNM stage (P=0.899, P=0.888). A total of 86 patients in the SOX subgroup (34.2%) experienced AEs, similar to the rate found in the XELOX subgroup (104 patients or 41.4%; P=0.098).
The results suggested that adjuvant SOX chemotherapy has similar survival benefits compared to XELOX chemotherapy in Chinese patients with pathological stage II or III GC after D2 gastrectomy.
比较D2胃切除术后中国胃癌（GC）患者辅助性SOX（S-1和奥沙利铂）与XELOX（卡培他滨和奥沙利铂）化疗的预后。
这是一项针对复旦大学附属中山医院2010年1月至2017年6月期间接受D2胃切除术并接受辅助性SOX或XELOX治疗的II-III期GC患者的真实世界研究。通过倾向评分匹配对患者进行匹配。主要和次要终点分别为无病生存期（DFS）和总生存期（OS）。比较不良事件（AE）。
共纳入552例患者。中位随访时间为24.9个月。XELOX组和SOX组在DFS（中位值，44.4对41.2个月；HR=1.17，95%CI：0.92-1.48）和OS（中位值，61.5对65.3个月；HR=1.01，95%CI：0.73-1.39）方面无差异。基于性别（P=0.949，P=0.990）、年龄（P=0.303，P=0.392）、劳伦分型（P=0.362，P=0.573）、胃切除类型（P=0.607，P=0.989）和病理TNM分期（P=0.899，P=0.888）的所有亚组中，SOX和XELOX在DFS和OS方面均无显著差异。SOX亚组共有86例患者（34.2%）发生AE，与XELOX亚组（104例患者或41.4%；P=0.098）的发生率相似。
结果表明，在D2胃切除术后病理分期为II或III期的中国GC患者中，辅助性SOX化疗与XELOX化疗的生存获益相似。
